

# Rosa Ayala

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3688398/publications.pdf>

Version: 2024-02-01

89  
papers

1,843  
citations

361296

20  
h-index

289141

40  
g-index

91  
all docs

91  
docs citations

91  
times ranked

3542  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Minimal Residual Disease Using Liquid Biopsies in Hematological Malignancies. <i>Cancers</i> , 2022, 14, 1310.	1.7	16
2	Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea. <i>Cancer</i> , 2022, 128, 2441-2448.	2.0	14
3	Monitoring of clonal evolution of acute myeloid leukemia identifies the leukemia subtype, clinical outcome and potential new drug targets for post-remission strategies or relapse. <i>Haematologica</i> , 2021, 106, 2325-2333.	1.7	18
4	Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial. <i>Blood Advances</i> , 2021, 5, 760-770.	2.5	18
5	A typical acute lymphoblastic leukemia JAK2 variant, R683G, causes an aggressive form of familial thrombocytosis when germline. <i>Leukemia</i> , 2021, 35, 3295-3298.	3.3	2
6	The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial. <i>Cancers</i> , 2021, 13, 2458.	1.7	7
7	Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols. <i>British Journal of Haematology</i> , 2021, , .	1.2	2
8	Clonal hematopoiesis-defining mutations have no impact on the development of thrombosis in a cohort of patients with myeloid pathology. <i>Leukemia Research</i> , 2021, 108, 106613.	0.4	0
9	Increased von Willebrand factor antigen and low ADAMTS13 activity are related to poor prognosis in covid-19 patients. <i>International Journal of Laboratory Hematology</i> , 2021, 43, O152-O155.	0.7	23
10	Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project. <i>Haematologica</i> , 2021, 106, 3079-3089.	1.7	15
11	Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens. <i>Scientific Reports</i> , 2021, 11, 20745.	1.6	11
12	Does RAD21 Co-Mutation Have a Role in DNMT3A Mutated AML? Results of Harmony Alliance AML Database. <i>Blood</i> , 2021, 138, 608-608.	0.6	0
13	Nationwide Laboratory Network for AML Cross-Validated NGS Studies: Results from a Real-Life Cohort of the Pethema Group. <i>Blood</i> , 2021, 138, 1302-1302.	0.6	0
14	Triple Combination of Ruxolutinib, Nilotinib and Prednisone Is Safe and Shows Promising Activity for the Treatment of Myelofibrosis Patients, Results of a Phase Ib Clinical Trial (RUNIC). <i>Blood</i> , 2021, 138, 3655-3655.	0.6	0
15	Potential Utility of Circulating Tumor DNA Monitoring in Primary Mediastinal B-Cell Lymphoma Treated with R-DA-EPOCH. <i>Blood</i> , 2021, 138, 4491-4491.	0.6	0
16	Integrated Multidimensional Flow Cytometry (MFC) and Next-Generation Sequencing (NGS) to Reconstruct Evolutionary Patterns from Dysplasia to Acute Myeloid Leukemia (AML). <i>Blood</i> , 2021, 138, 520-520.	0.6	0
17	Impact of Gender on Molecular AML Subclasses - a Harmony Alliance Study. <i>Blood</i> , 2021, 138, 3438-3438.	0.6	0
18	The Spliceosome As a New Therapeutic Target in Cytarabine-Resistant Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 3334-3334.	0.6	0

#	ARTICLE	IF	CITATIONS
19	Harmony Alliance Provides a Machine Learning Researching Tool to Predict the Risk of Relapse after First Remission in AML Patients Treated without Allogeneic Haematopoietic Stem Cell Transplantation. <i>Blood</i> , 2021, 138, 4041-4041.	0.6	2
20	MPL S505C enhances driver mutations at W515 in essential thrombocythemia. <i>Blood Cancer Journal</i> , 2021, 11, 188.	2.8	2
21	Impact of COVID-19 in patients with multiple myeloma based on a global data network. <i>Blood Cancer Journal</i> , 2021, 11, 198.	2.8	25
22	Novel DNMT3A Germline Variant in a Patient with Multiple Paragangliomas and Papillary Thyroid Carcinoma. <i>Cancers</i> , 2020, 12, 3304.	1.7	5
23	Clinical course and risk factors for mortality from COVID-19 in patients with haematological malignancies. <i>European Journal of Haematology</i> , 2020, 105, 597-607.	1.1	73
24	Jumping Translocation in a Patient with Acute Leukemia and Fatal Evolution. <i>Case Reports in Oncology</i> , 2020, 13, 1026-1030.	0.3	0
25	High-sensitivity microsatellite instability assessment for the detection of mismatch repair defects in normal tissue of biallelic germline mismatch repair mutation carriers. <i>Journal of Medical Genetics</i> , 2020, 57, 269-273.	1.5	20
26	Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with <i>in vivo</i> chemosensitivity. <i>British Journal of Haematology</i> , 2020, 189, 672-683.	1.2	11
27	miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk. <i>Leukemia</i> , 2020, 34, 2648-2659.	3.3	18
28	Analysis of SNP Array Abnormalities in Patients with DE NOVO Acute Myeloid Leukemia with Normal Karyotype. <i>Scientific Reports</i> , 2020, 10, 5904.	1.6	8
29	A novel targeted RNA-Seq panel identifies a subset of adult patients with acute lymphoblastic leukemia with BCR-ABL1-like characteristics. <i>Blood Cancer Journal</i> , 2020, 10, 43.	2.8	10
30	Características clínico-biológicas de los pacientes con mielofibrosis: un análisis de 1.000 casos del Registro Español de Mielofibrosis. <i>Medicina Clínica</i> , 2020, 155, 152-158.	0.3	3
31	Measurable Residual Disease (MRD) in Elderly Acute Myeloid Leukemia (AML): Results from the Pethema-Flugaza Phase III Clinical Trial. <i>Blood</i> , 2020, 136, 32-32.	0.6	0
32	Study of the Role of Splicing Factor SRRM2 in Cytarabine Treatment Resistance in Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 8-9.	0.6	0
33	Validation of the High-Risk Prognostic Score Defined By the Presence of Mutations in NRAS or TP53 in a Cohort of 497 Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 4-5.	0.6	0
34	Detection of Emerging Resistant Clones in Philadelphia-Positive Leukemia Patients Exposed to Tyrosine Kinase Inhibitors. Correlation of cDNA and Gdna Approaches. <i>Blood</i> , 2020, 136, 6-8.	0.6	1
35	Differences in the Mutational Landscape of Myeloid Malignancies (acute myeloid leukemia,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 TFS 136, 41-42.	0.6	0
36	Minimal Residual Disease Monitoring from Liquid Biopsy By Next Generation Sequencing in Follicular Lymphoma Patients. <i>Blood</i> , 2020, 136, 31-33.	0.6	2

#	ARTICLE	IF	CITATIONS
37	A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia. <i>Haematologica</i> , 2019, 104, 288-296.	1.7	36
38	Protein Carbonylation in Patients with Myelodysplastic Syndrome: An Opportunity for Deferasirox Therapy. <i>Antioxidants</i> , 2019, 8, 508.	2.2	4
39	Minimal Residual Disease Monitoring with Next-Generation Sequencing Methodologies in Hematological Malignancies. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2832.	1.8	42
40	MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia. <i>Scientific Reports</i> , 2019, 9, 18630.	1.6	24
41	Clinical Utility of a Next-Generation Sequencing Panel for Acute Myeloid Leukemia Diagnostics. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 228-240.	1.2	24
42	Different Clinical Implications of Kinase Domain BCR-ABL1 Variants Detected in Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia Patients. <i>Blood</i> , 2019, 134, 5368-5368.	0.6	0
43	Multicenter, Open-Label, Single Arm, Phase II Exploratory Study to Evaluate the Effect of a One-Year Consolidation Treatment with Ponatinib 15 Mg on Treatment Free-Remission Rate in Patients with Philadelphia-Positive Chronic Myeloid Leukemia, Who Had Previously Achieved a Deep Molecular Response with Imatinib (PonaZero study). <i>Blood</i> , 2019, 134, 5904-5904.	0.6	0
44	Wilms Tumor 1 gene expression levels improve risk stratification in <sc>AML</sc> patients. Results of a multicentre study within the Spanish Group for Molecular Biology in Haematology. <i>British Journal of Haematology</i> , 2018, 181, 542-546.	1.2	4
45	Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?. <i>Annals of Hematology</i> , 2018, 97, 2089-2098.	0.8	18
46	Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing. <i>Haematologica</i> , 2018, 103, e544-e548.	1.7	13
47	rs2431697, a Polymorphism of Mir-146a, Is a Precozing Marker of Progression to Secondary Myelofibrosis: New Epigenetic Regulation of Jak/Stat3 Signaling. <i>Blood</i> , 2018, 132, 3072-3072.	0.6	0
48	Study of the Clinical Significance of the Length of FLT3-ITD in Acute Myeloid Leukemia Patients. <i>Blood</i> , 2018, 132, 5278-5278.	0.6	0
49	Protein Carbonylation Pattern Is Altered in Myelodysplastic Syndromes. <i>Blood</i> , 2018, 132, 5502-5502.	0.6	0
50	Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma. <i>Leukemia</i> , 2017, 31, 1446-1449.	3.3	44
51	Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid. <i>Annals of Hematology</i> , 2017, 96, 1069-1075.	0.8	21
52	PTCH1 is a reliable marker for predicting imatinib response in chronic myeloid leukemia patients in chronic phase. <i>PLoS ONE</i> , 2017, 12, e0181366.	1.1	8
53	Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes. <i>Oncotarget</i> , 2017, 8, 106948-106961.	0.8	38
54	Ocena minimalnej choroby resztkowej w szpiczaku plazmocytowym. <i>Hematologia</i> , 2017, 8, 219-227.	0.0	0

#	ARTICLE	IF	CITATIONS
55	Circulating Immune Complexes of IgA Bound to Beta 2 Glycoprotein are Strongly Associated with the Occurrence of Acute Thrombotic Events. <i>Journal of Atherosclerosis and Thrombosis</i> , 2016, 23, 1242-1253.	0.9	32
56	Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. <i>Haematologica</i> , 2016, 101, 926-931.	1.7	118
57	Leucemia mieloide cr3nica en Espa±a: sus caracter3sticas de presentaci3n han cambiado. Secci3n espa±ola del registro poblacional EUTOS. <i>Revista Clinica Espanola</i> , 2016, 216, 293-300.	0.2	9
58	<scp>CALR</scp> mutations screening should not be studied in splanchnic vein thrombosis. <i>British Journal of Haematology</i> , 2015, 170, 588-589.	1.2	15
59	Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia. <i>Annals of Hematology</i> , 2015, 94, 911-918.	0.8	49
60	Myeloproliferative neoplasm in a thalassaemic patient: response to treatment with a JAK inhibitor. <i>Annals of Hematology</i> , 2015, 94, 1237-1239.	0.8	5
61	JAK2 exon 12 mutations were not found in liver transplant recipients with or without pretransplant portal vein thrombosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 362-363.	0.8	3
62	Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm. <i>Leukemia</i> , 2014, 28, 823-829.	3.3	148
63	Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. <i>Blood</i> , 2014, 123, 3073-3079.	0.6	380
64	Proteomic analysis reveals heat shock protein 70 has a key role in polycythemia Vera. <i>Molecular Cancer</i> , 2013, 12, 142.	7.9	20
65	Clinical applicability and prognostic significance of molecular response assessed by fluorescentâ€<scp>PCR</scp> of immunoglobulin genes in multiple myeloma. Results from a <scp>GEM</scp>/<scp>PETHEMA</scp> study. <i>British Journal of Haematology</i> , 2013, 163, 581-589.	1.2	27
66	Inhibition of related JAK/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm. <i>British Journal of Haematology</i> , 2013, 161, 667-676.	1.2	20
67	Correlation of WT1 expression with the burden of total and residual leukemic blasts in bone marrow samples of acute myeloid leukemia patients. <i>Cancer Genetics</i> , 2012, 205, 190-191.	0.2	14
68	Obesity is an independent risk factor for pre-transplant portal vein thrombosis in liver recipients. <i>BMC Gastroenterology</i> , 2012, 12, 114.	0.8	50
69	Acute myeloid leukemia and transcription factors: role of erythroid Kr3/4ppel-like factor (EKLF). <i>Cancer Cell International</i> , 2012, 12, 25.	1.8	5
70	Use of <scp>S</scp>orafenib as an effective treatment in an <scp>AML</scp> patient carrying a new point mutation affecting the <scp>J</scp>uxtamembrane domain of <i><scp>FLT</scp>3</i>. <i>British Journal of Haematology</i> , 2012, 158, 555-558.	1.2	5
71	Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy. <i>Haematologica</i> , 2011, 96, 1470-1477.	1.7	59
72	Recipient and donor thrombophilia and the risk of portal venous thrombosis and hepatic artery thrombosis in liver recipients. <i>BMC Gastroenterology</i> , 2011, 11, 130.	0.8	31

#	ARTICLE	IF	CITATIONS
73	Epigenomic profiling in polycythaemia vera and essential thrombocythaemia shows low levels of aberrant DNA methylation. <i>Journal of Clinical Pathology</i> , 2011, 64, 1010-1013.	1.0	20
74	Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia. <i>Annals of Hematology</i> , 2011, 90, 939-946.	0.8	7
75	Simplifying the detection of MUTYH mutations by high resolution melting analysis. <i>BMC Cancer</i> , 2010, 10, 408.	1.1	5
76	Real-time PCR quantification of haematopoietic chimerism after transplantation: a comparison between TaqMan and hybridization probes technologies. <i>International Journal of Laboratory Hematology</i> , 2010, 32, e17-25.	0.7	6
77	Post-Transplant Myelodysplastic Syndromes In Pediatric Liver Transplantation Recipients: a Report of Two Cases. <i>Blood</i> , 2010, 116, 4978-4978.	0.6	2
78	Long-term follow-up of donor chimerism and tolerance after human liver transplantation. <i>Liver Transplantation</i> , 2009, 15, 581-591.	1.3	19
79	Living Donor Liver Transplantation: Usefulness of Hemostatic and Prothrombotic Screening in Potential Donors. <i>Transplantation Proceedings</i> , 2009, 41, 3791-3795.	0.3	16
80	High Resolution Melting Analysis for JAK2 Exon 14 and Exon 12 Mutations. <i>Journal of Molecular Diagnostics</i> , 2009, 11, 155-161.	1.2	48
81	Long-Term Follow-up of Donor Chimerism and Tolerance After Human Liver Transplantation.. <i>Blood</i> , 2009, 114, 3534-3534.	0.6	0
82	Validity test study of JAK2 V617F and allele burden quantification in the diagnosis of myeloproliferative diseases. <i>Annals of Hematology</i> , 2008, 87, 741-749.	0.8	43
83	Evaluation of minimal residual disease in multiple myeloma patients by fluorescent polymerase chain reaction: the prognostic impact of achieving molecular response. <i>British Journal of Haematology</i> , 2008, 142, 766-774.	1.2	52
84	Importance of JAK2 V617F Allele Burden in the Diagnosis of Myeloproliferative Diseases and Its Association to Age.. <i>Blood</i> , 2007, 110, 4654-4654.	0.6	0
85	Application of Self-Quenched JH Consensus Primers for Real-Time Quantitative PCR of IGH Gene to Minimal Residual Disease Evaluation in Multiple Myeloma. <i>Journal of Molecular Diagnostics</i> , 2006, 8, 364-370.	1.2	1
86	Breast Cancer-Specific mRNA Transcripts Presence in Peripheral Blood After Adjuvant Chemotherapy Predicts Poor Survival Among High-Risk Breast Cancer Patients Treated With High-Dose Chemotherapy With Peripheral Blood Stem Cell Support. <i>Journal of Clinical Oncology</i> , 2006, 24, 3611-3618.	0.8	36
87	The use of fluorescent molecular beacons in real time PCR of IgH gene rearrangements for quantitative evaluation of multiple myeloma. <i>International Journal of Laboratory Hematology</i> , 2004, 26, 31-35.	0.2	6
88	Grupos de riesgo citogenético en la leucemia mieloide aguda: comparación de los modelos adoptados por los grupos MRC (Medical Research Council, del Reino Unido) y SWOG (Southwest Oncology) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50		
89	Clinical Course and Risk Factors for Mortality from COVID-19 in Patients with Hematological Malignancies. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0